Ztalmy

Active Ingredient(s): Ganaxolone
FDA Approved: * March 18, 2022
Pharm Company: * MARINUS PHARAMCEUTICALS, INC
Category: Anticonvulsant

Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).[1][2] Ganaxolone was approved for medical use in the United States in March 2022.[1] Contents 1 Pharmacology 1.1 Mechanism of action 2 Chemistry 3 Research 3.1 Clinical trials 4 References 5 External links Pharmacology Mechanism of action The exact mechanism of actio... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.